Affordable Access

Publisher Website

Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside.

Authors
  • Zhang, Li1
  • Yang, Ling1
  • Chu, Huikuan1
  • 1 Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. , (China)
Type
Published Article
Journal
Journal of clinical and translational hepatology
Publication Date
Aug 28, 2023
Volume
11
Issue
4
Pages
958–966
Identifiers
DOI: 10.14218/JCTH.2022.00408
PMID: 37408823
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Primary biliary cholangitis (PBC) is a complex cholestatic liver disease with an unresolved etiology. The gut microbiota is composed of a dynamic community of bacteria, archaea, fungi, and viruses that have a key role in physiological processes related to nutrition, immunity, and host defense responses. A number of recent studies found that the composition of the gut microbiota of PBC patients was significantly altered, and reported that gut dysbiosis might arise during PBC development because of the close interactions of the liver and the gut. In light of the growing interest in this topic, the focus of this review is to characterize PBC gut microbiota alterations, the correlation between PBC pathology and the gut microbiota, and prospective therapies that target the altered gut microbiota, such as probiotics and fecal microbiota transplantation. © 2023 Authors.

Report this publication

Statistics

Seen <100 times